A Novel Blood Test as a Biomarker in Mental Health
Recruiting
Observational Study
Depression - Major Depressive Disorder
Schizophenia Disorder
Psychosis
Mania (Neurotic)
Alcohol Consumption
Anxiety Disorder (Panic Disorder or GAD)
Substance Use Disorders
Alcohol Use Disorder
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 19 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 500 (estimated)
- Sponsor
- Fraser Health · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This longitudinal, observational study aims to assess whether the characteristics of a novel blood peripheral biomarker can serve as indicators for depression and schizophrenia in patients at the Royal Columbian Hospital Psychiatric Clinics. The study will evaluate whether changes in these biomarker characteristics can help distinguish between depressed patients who do or do not respond to treatme…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
I. Age 19+. II. Informed consent by participant
III. Any of the following situations:
1. Suspected, new onset or established depression.
2. First episode of psychosis or suspected/established schizophrenia. IV. In the opinion of the Investigator, the participant will likely be…
Contacts